Glutaminase Inhibitor + Chemoradiation for Cervical Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
Advanced cervical cancer patients treated with standard of care (SOC) chemoradiation plus glutaminase inhibition with telaglenastat (CB-839) will have increased progression-free survival (PFS) compared to historical rates for patients receiving SOC chemoradiation alone.
Will I have to stop taking my current medications?
The trial protocol does not specify if you need to stop taking your current medications. However, if you are on therapeutic anticoagulation, you should be on a stable dose. It's best to discuss your specific medications with the trial team.
What safety data exists for the combination of glutaminase inhibitor, cisplatin, and radiation therapy in cervical cancer treatment?
Studies show that combining cisplatin with radiation therapy for cervical cancer is generally safe, with common side effects including nausea, vomiting, and anemia. Long-term effects can include gastrointestinal and urological issues, but adding cisplatin does not seem to increase these late toxicities.12345
What makes the Glutaminase Inhibitor + Chemoradiation treatment for cervical cancer unique?
This treatment is unique because it combines a glutaminase inhibitor with chemoradiation, potentially enhancing the effectiveness of traditional chemotherapy and radiation by targeting cancer cell metabolism, which is different from standard treatments that typically use cisplatin alone or with other drugs like paclitaxel.15678
What data supports the effectiveness of the treatment Glutaminase Inhibitor + Chemoradiation for Cervical Cancer?
Who Is on the Research Team?
Julie Schwarz, M.D., Ph.D.
Principal Investigator
Washington University School of Medicine
Are You a Good Fit for This Trial?
This trial is for adults over 18 with newly diagnosed advanced cervical cancer (stages III-IVA). They must have a certain level of blood cells, liver and kidney function, not be breastfeeding, and able to consent. Excluded are those with severe illnesses, prior treatments for this cancer or pelvic radiation, uncontrolled diabetes or HIV, pregnancy/breastfeeding women, and known allergies to the drugs used.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive 2 weeks of telaglenastat followed by 7 weeks of standard of care chemoradiation plus telaglenastat
Follow-up
Participants are monitored for safety and effectiveness after treatment
Late Toxicity Monitoring
Monitoring for late toxicities related to treatment
What Are the Treatments Tested in This Trial?
Interventions
- Cisplatin
- Radiation treatment
- Telaglenastat
Cisplatin is already approved in European Union, United States, Canada, Japan for the following indications:
- Testicular cancer
- Ovarian cancer
- Cervical cancer
- Bladder cancer
- Head and neck cancer
- Esophageal cancer
- Lung cancer
- Mesothelioma
- Brain tumors
- Neuroblastoma
- Testicular cancer
- Ovarian cancer
- Cervical cancer
- Bladder cancer
- Head and neck cancer
- Esophageal cancer
- Lung cancer
- Mesothelioma
- Brain tumors
- Neuroblastoma
- Testicular cancer
- Ovarian cancer
- Cervical cancer
- Bladder cancer
- Head and neck cancer
- Esophageal cancer
- Lung cancer
- Mesothelioma
- Brain tumors
- Neuroblastoma
- Testicular cancer
- Ovarian cancer
- Cervical cancer
- Bladder cancer
- Head and neck cancer
- Esophageal cancer
- Lung cancer
- Mesothelioma
- Brain tumors
- Neuroblastoma
Find a Clinic Near You
Who Is Running the Clinical Trial?
Washington University School of Medicine
Lead Sponsor
National Cancer Institute (NCI)
Collaborator
Calithera Biosciences, Inc
Industry Sponsor